Additional file 1: Table S1. of A mortality prediction rule for non-elderly patients with community-acquired pneumonia

Definition of scores for each item of the Barthel index used in this study. (DOCX 49.2kb

Study population in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.

<p>Study population in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.</p

List of adverse events in the present study.

<p>List of adverse events in the present study.</p

Trial Profile.

<p>Trial Profile.</p

Laboratory data for the azithromycin-oseltamivir combined therapy and oseltamivir monotherapy groups.

<p>Laboratory data for the azithromycin-oseltamivir combined therapy and oseltamivir monotherapy groups.</p

Comparison of inflammatory marker levels in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.

<p>Serial test results (on days 0, 2, and 5) for the 8 inflammatory markers were compared between the groups with and without AZM. The horizontal and vertical lines depicted in the scattergram represent the central 50% range (25–75 percentiles) and the median, respectively. In the graphs for interleukin 8 (IL-8), IL-12, and tumor necrosis factor α (TNF-α), missing central boxes or concordance of the left end of the box with the median indicate that the majority of the test results were lower than the limit of detection.</p

Improvement of influenza-related symptoms in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.

<p>Improvement of influenza-related symptoms in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.</p